&w=3840&q=100)
Blood test to diagnose Alzheimer's gets approval in US
Fujirebio Diagnostics created the test to assess the ratio of two proteins in the blood. The rato is associated with amyloid plaques in the brain, a hallmark of Alzheimer's that has thus far been diagnosed exclusively by brain imaging and spinal fluid research read more
The US approved the first blood test for Alzheimer's on Friday, potentially allowing patients to begin treatment sooner using newly approved medications that slow the spread of the terrible neurological illness.
Fujirebio Diagnostics created the test to assess the ratio of two proteins in the blood. The rato is associated with amyloid plaques in the brain, a hallmark of Alzheimer's that has thus far been diagnosed exclusively by brain imaging and spinal fluid research.
STORY CONTINUES BELOW THIS AD
'Alzheimer's disease impacts too many people – more than breast cancer and prostate cancer combined,' said Food and Drug Administration Commissioner Marty Makary.
'Knowing that 10 percent of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients.'
While they do not cure Alzheimer's, lecanemab and donanemab, two FDA-approved therapies that target amyloid plaque, have been demonstrated to somewhat moderate cognitive deterioration.
Advocates of intravenous antibody treatments, including many neurologists, claim they can provide patients a few more months of independence and are more likely to be beneficial if begun earlier in the disease's course.
In clinical trials, the blood test showed results that were mostly consistent with positron emission tomography (PET) brain scans and spinal fluid analyses.
'Today's clearance is an important step for Alzheimer's diagnosis, making it easier and potentially more accessible for US patients earlier in the disease,' said Michelle Tarver of the FDA's Center for Devices and Radiological Health.
The test is authorized for use in clinical settings for patients showing signs of cognitive decline, and results must be interpreted alongside other clinical information.
Alzheimer's is the most common form of dementia. It worsens over time, gradually robbing people of their memories and independence.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Amid staff crunch, FDA to appoint 40 food safety officers this week
Mumbai: After operating with just five food safety officers (FSOs) for nearly a year, the city's Food and Drug Administration (FDA) is expected to appoint at least 40 new FSOs by June 7, in a bid to address a severe staffing shortfall. The drug department under the FDA is similarly stretched thin with only five field officers in the city. It may take another year to reach its required strength of 25 to 30 here. Officials say the shortage significantly hampered inspections and enforcement, overburdening the limited staff. Following action taken against a Zepto facility in Dharavi on Sunday, FDA officials admitted they currently lack the manpower to inspect similar warehouses operated by delivery platforms. "Food safety officers are the field workers who conduct sampling and routine inspections. Without adequate numbers, essential tasks like testing for milk adulteration or checking ice quality can't happen at the large scale required," said Mangesh Mane, joint commissioner (Food). Although over 40 officers are expected to be appointed within days, Mane said training will take another month or two. "We expect them to join the workforce by October," he added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Switch to UnionBank Rewards Card UnionBank Credit Card Apply Now Undo FDA commissioner Rajesh Narvekar said the food division has 350 sanctioned posts, but only 132 are filled, leaving a gap of 218 officers. After repeated proposals to the govt and the Maharashtra Public Service Commission, 194 food safety officers and 8 assistant commissioners were finally selected, bringing the department's total strength to just over 300. However, according to food safety norms, one officer per 1,000 food business operators, the FDA needs at least 1,100 officers. The drug department, meanwhile, has 200 sanctioned posts but only 48 filled, with 152 vacancies still open. A revised recruitment proposal has been submitted to MPSC, but officials say it will take another year. The persistent shortfall is largely due to a prolonged pause in recruitment drives and a wave of retirements, promotions, and transfers over the past year or more. "We are meeting our targets by working extra hours. Leaves are being sacrificed, but we're trying not to let it affect our functioning," said an official from the drug department. Still, gaps remain. "There's no major problem due to shortfall in issuing manufacturing licenses after conducting their inspections," said Narvekar. "The problem is in monitoring retailers and wholesalers," he added. Abhay Pandey, president of the All Food and Drug Licence Holders Foundation, warned of serious public health consequences. "Random sampling at retail stores and distributor levels simply isn't happening for more than a year at a scale it should. Without it, there's no way to ensure quality control," he said.
Time of India
5 hours ago
- Time of India
Entrepreneur finds alternative to make areca plates safer after US ban
Mangaluru: Entrepreneur and researcher Nivedan Nempe has developed an innovative, eco-friendly alternative following the recent US ban on arecanut leaf sheath dinnerware. His intervention comes at a crucial time, as areca growers and industry experts from Karnataka's areca belt have appealed to Prime Minister Narendra Modi to seek the lifting of the restriction. The US Food and Drug Administration (FDA) issued an import alert banning dinnerware made from areca catechu sheaths, citing the presence of naturally occurring toxins that may migrate into food at unsafe levels. The FDA's concerns significantly impacted India's $400-500 million areca plate industry, with nearly 80–85% of exports directed to the US. Most manufacturers are concentrated in Dakshina Kannada and Shivamogga, and the ban threatens the livelihoods of many families. Nivedan, founder of Areca Tea and operating in Udupi and Shivamogga, acknowledged the FDA's concerns and told TOI: "As a preventive step, the FDA banned imports. But this severely affects Indian manufacturers. The Indian industry made efforts, including writing to the FDA, but the industry is at risk." In response, Nempe engineered a food-grade, anti-microbial paper lining that acts as a barrier between the food and the areca plate, preventing toxin migration and fungal growth. "The material is certified, heat-resistant up to 300°C, durable, printable, and gives a premium finish. It meets international safety standards without altering the existing production process," he said. While the innovation may increase production costs by 10–15%, Nivedan believes that it is the best way forward. "Our lab results were positive on all parameters. It even looks better than bagasse plates. My goal is to safeguard the industry and support the farmers by supplying this new food-grade paper."
Indian Express
8 hours ago
- Indian Express
‘The results were better than I anticipated': Bryan Johnson tries out hyperbaric oxygen therapy by spending 5,400 minutes in a pressurised tank for longevity
Biohacker and tech entrepreneur Bryan Johnson has been known to push the boundaries when it comes to experimenting with longevity. In one of his recent attempts, he turned to hyperbaric oxygen therapy (HBOT) — a treatment originally used to support wound healing and treat decompression sickness. Sharing his experience on Instagram, Bryan said, 'I spent 5,400 minutes in a pressurised tank, so you don't have to figure out how hyperbaric oxygen therapy works. It's a therapy that's used with elite athletes and stroke patients. But it's also a cutting-edge therapy for longevity.' He adds, 'You sit in a pressurised chamber, breathing pure oxygen. That extra oxygen may improve healing, boost performance, and may increase longevity. This is what I set out to do — 60 sessions in 90 days. The results were better than I anticipated. Some of the more noteworthy results is that my blood levels came back and showed I had no detectable levels of inflammation, a marker for cognitive decline, Alzheimer's reduced by 28.6%. My microbiome improved dramatically. My skin health dramatically improved and my telomere lengthened. This may be the most efficacious whole body rejuvenation therapy I've ever done.' Dr Gunasekar Vuppalapati MBBS, MS, FRCSEd, MCh, senior reconstructive, aesthetic plastic surgeon at GVG Invivo Hospitals and Apollo Hospitals, tells 'Hyperbaric Oxygen Therapy (HBOT) involves breathing pure oxygen in a pressurised chamber, allowing the extra oxygen to dissolve in the plasma, which is then circulated throughout the body. Practically, this increases the oxygen concentration available to every cell in the body, enhancing tissue repair and supporting healing processes caused by reduced capillary density, peripheral blood perfusion, cellular oxygenation in the end organs such as extremities, kidneys, retina etc.' A post shared by Bryan Johnson (@bryanjohnson_) When it comes to longevity or broad cellular repair in healthy individuals, he says, the evidence was minimal and largely anecdotal until the year 2020, when prospective trial results were published from Telaviv University, Israel, in the National Library of Medicine. 'This breakthrough study titled 'Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial' concluded that HBOT may induce significant senolytic effects, including significantly increasing telomere length and clearance of senescent cells in the ageing populations. However, long-term studies are required to determine the extent to which the lifespan and/or healthspan can be extended with HBOT as a supplementary therapy alongside the other regenerative anti-aging measures to slow the aging process,' Dr Vuppalapati notes. For otherwise healthy individuals, Dr Vuppalapati says, undergoing 60 sessions of HBOT in just three months is quite intensive. 'While HBOT is generally safe when administered under medical supervision, repeated exposure at such frequency can carry certain risks.' He adds, 'Known side effects include ear barotrauma (pressure-related ear pain or injury), sinus discomfort, and temporary vision changes like nearsightedness. Some individuals may experience oxygen toxicity, particularly with prolonged high-dose exposure, which can affect the central nervous system or lungs. However, this is very rare, unless the therapy exceeds the safety limits concerning pressure, the duration, and the necessary weekly breaks prescribed; and if done by unqualified personnel in facilities without a license.' There's also a theoretical risk that excessive oxidative stress, he asserts, caused by very high oxygen levels, could lead to cellular damage over time, particularly in someone without a medical need for the therapy. 'As clinicians, we always advocate for a measured and medically indicated approach to HBOT rather than overuse without clear benefit,' states the expert. DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.
